CDK2-IN-9

Cat. No.: HY-144811

Molecular Formula: $C_{21}H_{16}ClN_3O_4S$

Molecular Weight: 441.89

Target: CDK; Apoptosis

Pathway: Cell Cycle/DNA Damage; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CDK2-IN-9 is a potent CDK2 inhibitor with an IC_{50} of 0.63 μM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma[1].
IC_{50} & Target	CDK2 0.63 μM (IC_{50})
In Vitro	CDK2-IN-9 (compound 5c) shows antiproliferative activity with IC_{50}s of 3.03, 8.62, 62.52 μM for MDA-MB-435, SNB-75, WI-38 cells, respectively[1]. CDK2-IN-9 (24 h) induces apoptosis and cell cycle arrest in S and G2/M phase[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line:	MDA-MB-435, SNB-75 cells
Concentration:	3.03for MDA-MB-435 cells, 8.62 for SNB-75 cells
Incubation Time:	24 h
Result:	Induced apoptosis in MDA-MB-435 and SNB-75 cells with the percent of the total apoptosis of 28.65 and 44.22%, respectively.

Cell Cycle Analysis[1]

Cell Line:	MDA-MB-435, SNB-75 cells
Concentration:	
Incubation Time:	24 h
Result:	Induced cell cycle arrest at S phase and G2/M.

REFERENCES

[1]. Mohammed ER, et al. Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma. J Enzyme Inhib Med Chem. 2022 Dec;37(1):686-700.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA